← All organizations
Highest phase reached
Phase 4
First clinical trial
Jun 1, 1999Last known activity
Nov 16, 2025
Timeline
1990s
- Jun 1, 1999
Drugs for Neglected Diseases Initiative— Founded
Drugs by trial phase (46 distinct, 68 trials)
Phase 4 (8 own, 0 via acquisition)
Phase 3 (20 own, 0 via acquisition)
Phase 2 (11 own, 0 via acquisition)
Phase 1 (7 own, 0 via acquisition)
Indications
Studied for
- Acquired Immunodeficiency Syndrome
- Buruli Ulcer
- Chagas Disease
- Extensively Drug-Resistant Tuberculosis
- Filariasis
- Gonorrhea
- Hepatitis C
- HIV Infections
- HIV Seropositivity
- Immunologic Deficiency Syndromes
- Infections
- Leishmaniasis
- Leishmaniasis, Cutaneous
- Leishmaniasis, Visceral
- Mycetoma
- Neonatal Sepsis
- Parasitic Diseases
- Protozoan Infections
- Recurrence
- Sepsis
- Toxemia
- Trypanosomiasis
- Trypanosomiasis, African
- Tuberculosis
- Tuberculosis, Multidrug-Resistant
- Tuberculosis, Pulmonary
Recent trials (50)
- NCT06997159Lead sponsorPhase 2Nov 16, 2025
- NCT06606860CollaboratorPhase 1Nov 30, 2024
- NCT06356974Lead sponsorPhase 3Apr 8, 2024
- NCT05957978Lead sponsorPhase 2Jan 31, 2024
- NCT05947604Lead sponsorPhase 1Feb 9, 2023
- NCT05593666Lead sponsorPhase 2Nov 7, 2022
- NCT05433350Lead sponsorPhase 2/Phase 3Jul 15, 2022
- NCT05256017Lead sponsorPhase 2/Phase 3Dec 30, 2021
- NCT04920292CollaboratorPhase 1Dec 1, 2021
- NCT05180461Lead sponsorPhase 2Aug 30, 2021
- NCT04897516Study directorPhase 3Jul 28, 2021
- NCT04897516CollaboratorPhase 3Jul 28, 2021
- NCT04913610CollaboratorPhase 2May 29, 2021
- NCT04515186Lead sponsorPhase 3Nov 9, 2020
- NCT04270981Lead sponsorPhase 1Feb 10, 2020
Details
- Founded
- Geneva, CH Jun 1, 1999
- Last known activity
- Nov 16, 2025